Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial.
about
Management strategies in the treatment of neonatal and pediatric gastroenteritisEV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseasesEfficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against Enterovirus 71 and Coxsackieviruses A16 and A6 in MiceCryo-electron microscopy study of insect cell-expressed enterovirus 71 and coxsackievirus a16 virus-like particles provides a structural basis for vaccine development.How to understand the efficacy measurements for enterovirus type 71 vaccine?EV71 vaccine, an invaluable gift for children.The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy chinese infants and children.Peptidyl aldehyde NK-1.8k suppresses enterovirus 71 and enterovirus 68 infection by targeting protease 3CSafety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.Optimization and Characterization of Candidate Strain for Coxsackievirus A16 Inactivated VaccineDisease burden of enterovirus 71 in rural central China: A community-based survey.Studies on Inhibition of Proliferation of Enterovirus-71 by Compound YZ-LY-0.The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals.Seroprevalence of Enterovirus 71 Antibody Among Children in China: A Systematic Review and Meta-analysis.Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial.Comprehensive safety assessment of a human inactivated diploid enterovirus 71 vaccine based on a phase III clinical trialA novel, broad-spectrum inhibitor of enterovirus replication that targets host cell factor phosphatidylinositol 4-kinase IIIβ.Coxsackievirus A16 induced neurological disorders in young gerbils which could serve as a new animal model for vaccine evaluationAcetylcholinesterase-catalyzed hydrolysis allows ultrasensitive detection of pathogens with the naked eye.Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months.Progress on the research and development of inactivated EV71 whole-virus vaccines.Rheum emodin inhibits enterovirus 71 viral replication and affects the host cell cycle environment.Update of enterovirus 71 infection: epidemiology, pathogenesis and vaccine.Development of enterovirus 71 vaccines: from the lab bench to Phase III clinical trials.Update on the development of enterovirus 71 vaccines.Chinese vaccine products go global: vaccine development and quality control.Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine.Differential expression of miRNAs in enterovirus 71-infected cells.2-Year Efficacy, Immunogenicity, and Safety of Vigoo Enterovirus 71 Vaccine in Healthy Chinese Children: A Randomized Open-Label Study.Virus-inhibiting activity of dihydroquercetin, a flavonoid from Larix sibirica, against coxsackievirus B4 in a model of viral pancreatitis.Enhanced enterovirus 71 virus-like particle yield from a new baculovirus design.A booster dose of an inactivated enterovirus 71 vaccine in chinese young children: a randomized, double-blind, placebo-controlled clinical trial.Sophocarpine against enterovirus 71 in vitro.Immunopathogenesis and Virus-Host Interactions of Enterovirus 71 in Patients with Hand, Foot and Mouth Disease.Epidemiological and serological surveillance of hand-foot-and-mouth disease in Shanghai, China, 2012-2016.Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints.
P2860
Q27004496-08E611AC-89CC-4649-BFAC-4EE88382380CQ28076658-33403C18-AF8C-4C11-83BD-9DB47A0BF77EQ28606867-93EBA2F9-A009-4089-8C4F-C126F1B4BF74Q33887710-185FB2EA-E99B-4B6C-A5CA-99FC55A35335Q34033907-21C47637-537D-4831-B6B7-165FCF7A9161Q34540559-DFBAC288-B382-451F-8946-1E0223D57575Q35048558-58D2A1F8-5B78-43B0-AF59-3012982FD5D0Q35385360-A0761397-DB99-41E1-9EEB-2CACDE4D4C26Q35887288-8047F3CE-D0EB-4FE5-920B-BFA015556E59Q35895319-3F21E8C3-E227-47A0-BA72-ACAD257CEC44Q36256473-2B81105D-CF2A-48B3-AA1C-BECC66B56963Q36274964-1D7FD77D-15D2-45D5-A026-DC6FF72C07D3Q36389012-1E75311A-DC09-457C-A0AE-57407F5FF198Q36479953-66990827-E81E-43B5-A235-76081EC3F244Q36977606-8A650A87-F3C0-45F1-AC2A-9C2334DF23E5Q37130763-2EA9D7E2-E491-4F4A-BCE1-8B68AE18F1B5Q37263877-F0DDF0EF-FDCF-44FD-BFAE-C601ADB0339BQ37281676-638062F1-32AD-4329-A37E-30283A971E29Q37418707-656BD199-4786-46CD-B4FC-38560B3B8817Q37469307-2073E781-7DCD-4662-8766-109328FC4E81Q37530094-CF438A28-D159-4516-96F4-4BF54A28B836Q37688743-04C3C983-7EEF-4EC0-BF30-AF4BCFF473A6Q38192021-05D7249F-D9F7-4306-975F-A44E73C2B6D4Q38195326-61E92468-CAA5-4774-9E96-99E7DFCF4498Q38225695-E5ADF0AE-E151-4201-8486-1149CB9BF8E8Q38362086-129DE157-C3C0-40D1-9AF5-98DFDAF0019FQ38840182-E6723392-79AE-4BC4-800E-C75F7A71A18BQ38885207-35E65A25-AAEF-48AD-B411-56605A22150DQ40376000-0221224F-1078-4999-BEC3-EFD8C244E1F2Q40968334-4F916B14-67FB-4135-9CAF-AF827CD2FC3AQ41209873-A4BB8643-986D-45C6-AF9D-C9DC2E04F3FFQ42231743-E446B40E-48B2-4B49-931A-3800122172CBQ42376294-FEF2CC59-96A4-4A52-99F4-AD233CB3CB53Q47145137-E2CF56B8-2B19-41DC-9A93-F90D8259CC8EQ47549540-1C8EF021-4A72-4703-853D-47EDAD0CB6B3Q54079810-75E06029-0A3B-4843-95B9-A4619ECB2547
P2860
Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Immunogenicity and safety of a ...... rolled phase 2 clinical trial.
@ast
Immunogenicity and safety of a ...... rolled phase 2 clinical trial.
@en
Immunogenicity and safety of a ...... rolled phase 2 clinical trial.
@nl
type
label
Immunogenicity and safety of a ...... rolled phase 2 clinical trial.
@ast
Immunogenicity and safety of a ...... rolled phase 2 clinical trial.
@en
Immunogenicity and safety of a ...... rolled phase 2 clinical trial.
@nl
prefLabel
Immunogenicity and safety of a ...... rolled phase 2 clinical trial.
@ast
Immunogenicity and safety of a ...... rolled phase 2 clinical trial.
@en
Immunogenicity and safety of a ...... rolled phase 2 clinical trial.
@nl
P2093
P1433
P1476
Immunogenicity and safety of a ...... rolled phase 2 clinical trial.
@en
P2093
Fan-Yue Meng
Feng-Cai Zhu
Feng-Xiang Li
Heng-Ming Ge
Hui-Jie Guo
Jing-Xin Li
Jun-Zhi Wang
P304
P356
10.1016/S0140-6736(12)61764-4
P407
P577
2013-03-01T00:00:00Z